E4 IAI Flashcards

1
Q

IAI definitions:
Uncomplicated (2)

A
  • confined within visceral structure
  • does NOT extend into peritoneum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

IAI definitions:
complicated (1)

A
  • extends beyond a single organ INTO the peritoneal space and associated with peritonitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IAI definitions:
Community-acquired infection (2)

A
  • within 48 hours of hospital admission
  • caused by normal intra-abdominal flora
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

IAI definitions:
Healthcare-associated infection (2)

A
  • 48 hours of hospital admission
  • healthcare exposure in last 12 months (hospitalization/recent surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

most common source of bacterial contamination for SBP

A

no obvious source

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

patients at highest risk for SBP (2)

A
  • hepatic failure and ascites - alcoholic cirrhosis*
  • continuous ambulatory peritoneal dialysis (CAPD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

T or F:
SBP is most commonly polymicrobial

A

false, mono

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

4 common bacteria for SBP and most common one

A
  • e coli *
  • streptococci
  • enterococci
  • s aureus (more common with CAPD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

1 main clinical presentation of SBP

A

ab pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

diagnosis of SBP

A
  • s/sxs of infxn
  • low ascitic fluid protein (<2.5)
  • absolute neutrophil count > 250 **
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

4 tx options for empiric tx of SBP + most common one

A
  • ceftriaxone **
  • Cefepime
  • Piper/tazo
  • Meropenem
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tx of SBP with MRSA risk (3 kinda)

A
  • same as empiric but ADD one of the following:
  • vanc
  • linezolid
  • dapto
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tx for anaerobic coverage in SBP (3)

A
  • b-lactam/b-lactam inhibitor
  • carbapenem
  • add metro
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when do you transition to oral therapy in SBP?

A

once clinical stability is achieved

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SBP duration in pts with cirrhosis and ascites

A

5-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Secondary prophylaxis is recc in pts with SBP + cirrhosis and ascites. what are the two drug options for this?

A
  • bactrim
  • cipro
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

duration of tx for pt w/ peritonitis undergoing CAPD

A

14-21 days bc prosthetic material is involved

18
Q

Secondary peritonitis
A. Monomicrobial
B. Polymicrobial

19
Q

what kind of bacteria did he say play a key role in secondary peritonitis

20
Q

what is the most common anaerobic bacteria in secondary peritonitis

A

bacteroides spp (B. fragilis most common)

21
Q

most common aerobic GN bacteria in secondary peritonitis

A

E coli, can also be kleb, entero, or proteus

22
Q

most common aerobic GP bacteria in secondary peritonitis

A

strep spp (usually viridans), can also be enterococcus

23
Q

only fungi species he talks about in secondary peritonitis

24
Q

what is the main thing he said that makes IAI’s unique

A

multiple organ systems are affected

25
Q

Bacterial synergy in IAI:
________ create optimal environment for anaerobic bacteria. ________ cause abscess formation and have several virulence factors

A

enterobacterales (e.g. E. coli)
anaerobes

26
Q

im ignoring clin pres

27
Q

2 imaging things we use for diagnosis in IAI

A

CT scan + Xray

28
Q

4 examples of source control procedures for IAI’s

A
  • repair perforation
  • resection of infected organs
  • removal of foreign material
  • drain purulent collections
29
Q

when are agents generally not recc in tx for IAI’s

A

resistance rates exceed 10-20%
(must look at antibiogram)

30
Q

3 general considerations for empiric selection in IAI’s

A
  1. high likelihood to cover common organisms
  2. consider if enterococci coverage is necessary
  3. consider if antifungal coverage is necessary
31
Q

6 times enterococci coverage is considered necessary in empiric selection for IAI

A
  1. high severity
  2. hx of recent cephalosporin use
  3. immunocompromised
  4. biliary source of infection
  5. hx of valvular heart disease
  6. prosthetic intravascular material
32
Q

when is enterococci coverage not necessary in IAI

A

mild/mod community-acquired IAI*

33
Q

CA-IAI mild/mod empiric regimen options (5)

A
  1. ceftriaxone +metro
  2. cefazolin+ metro
  3. cefoxitin
  4. ertapenem
  5. tigecycline
34
Q

what drug did he specifically say is not recc empirically for IAI and why

A

amp/sulb&raquo_space; e coli resistance

35
Q

CA-IAI, high severity AND HA empiric options (3)

A
  • piper/tazo
  • meropenem
  • cefepime + metro
36
Q

1 tx option for IAI caused by candida

A

fluconazole

37
Q

1 tx option for candida species other than albicans in IAI

A

micafungin tf lol

38
Q

“really important note about anaerobic bacteria”

A

common to maintain anaerobic coverage even if culture does not isolate it

39
Q

3 common oral AB regimens for IAI

A
  • amox/clav (q8h*/12h)
  • cefpodoxime +metro
  • cephalexin +metro
40
Q

4 common oral IAI regimens that say “if possible, confirm susceptibility”

A
  • cefadroxil + metro
  • cipro + metro
  • levo + metro
  • bactrim + metro
41
Q

general oral tx duration for IAI

A

4-7 days after source control